Mineralys Therapeutics, Inc.
MLYS
$13.48
-$0.25-1.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -188.51M | -177.81M | -153.25M | -119.67M | -90.80M |
| Total Depreciation and Amortization | 50.00K | 43.00K | 28.00K | 17.00K | 8.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.85M | 1.93M | -475.00K | -1.29M | -2.02M |
| Change in Net Operating Assets | -9.05M | 9.52M | 25.25M | 23.64M | 5.27M |
| Cash from Operations | -192.66M | -166.31M | -128.45M | -97.30M | -87.54M |
| Capital Expenditure | -37.00K | -96.00K | -96.00K | -59.00K | -59.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.07M | 115.06M | 23.40M | -52.24M | -76.11M |
| Cash from Investing | 78.04M | 114.96M | 23.30M | -52.30M | -76.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 189.60M | 116.58M | 116.51M | 116.66M | 116.53M |
| Repurchase of Common Stock | -- | -- | -- | -- | -581.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -382.00K | -435.00K | -388.00K | -347.00K | -63.00K |
| Cash from Financing | 189.22M | 116.14M | 116.13M | 116.31M | 115.88M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.59M | 64.79M | 10.97M | -33.28M | -47.83M |